FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERS	HР
---	----

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response	: 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Edris Badreddin				2. Issuer Name and Ticker or Trading Symbol SpringWorks Therapeutics, Inc. [SWTX]								ck all applic Directo Officer	tionship of Reportin all applicable) Director Officer (give title		10% Ov Other (s	Owner r (specify			
(Last)	`	irst) KS THERAPEU	(Middle) TICS, INC.			ate o 06/2		Trans	action (Mo	(Month/Day/Year)					below)	nief Oper	ating	below) Officer	
100 WASHINGTON BLVD.																			
(Street)	ORD C	Γ	06902				4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)											Person				9	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transc Date (Month/L				action Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 3, 4) 3			N) or 4 and	5. Amour Securitie Beneficia Owned F Reported	es Formally (D) (Sollowing (I) (II)		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
						Code	v	Amount	(A) or (D)		Price	Transacti (Instr. 3 a	ion(s)			(Instr. 4)			
Common Stock ⁽¹⁾ 01/06				01/06	5/2022		A ⁽¹⁾		26,12	26,124 A		(1)	327,665			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Tr Security or Exercise (Month/Day/Year) if any Co		ransac Code (Ir	ansaction of lode (Instr. Derivative (6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)			Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				c	ode	v	(A)		Date Exercisab		Expiration Date	Title	or Nui of	mber ares					
Stock Option (Right to Buy)	\$59.46	01/06/2022			A		81,420		(2)	0	1/06/2032	Common Stock	81	,420	\$0	81,42	0	D	

Explanation of Responses:

- 1. This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025.
- 2. This option shall vest in 48 equal monthly installments subject to continued service to the company by the Reporting Person.

/s/ Francis I. Perier, Jr. as Attorney-in Fact

01/10/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.